Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches

Uccello, Mario; Boussios, Stergios; Samartzis, Eleftherios Pierre; Moschetta, Michele

doi:10.21037/atm.2020.04.15

Cited by 28 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to the type of ovarian cancer, EOC represents the vast majority of cases in comparison with NEOC [62]. In addition, NEOC, especially malignant germ cell tumors, is more sensitive to chemotherapy [63]. However, prognostic analysis based on pathological type in this study showed that there was no significant difference between EOC and NEOC, and no significant differences in OS and PFS were observed based on log-rank tests in these two stratified analyses.…”

Section: Discussioncontrasting

confidence: 55%

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis

Pei

Gou

et al. 2021

Oncol Ther

View full text Add to dashboard Cite

Introduction:Based on the available data on ovarian cancer during pregnancy, we performed a review and meta-analysis to evaluate the efficacy and safety of platinum-based chemotherapy against ovarian cancer during pregnancy. Methods: We systematically searched three databases including the PubMed, Embase, and Cochrane Library databases for articles published from January 1986 to December 2020 using the following terms: ''ovarian tumors OR ovarian carcinoma OR adnexal masses OR ovarian cancer'' AND ''pregnancy'' AND ''chemotherapy.'' Two authors (Yaping Pei and Yuanfeng Gou) independently searched the literature and extracted data from each eligible study. The outcome measures were overall survival (OS) and progression-free survival (PFS).

show abstract

Section: Discussioncontrasting

confidence: 55%

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis

Pei

Gou

et al. 2021

Oncol Ther

View full text Add to dashboard Cite

show abstract

“…The long-term side effects of platinum-based chemotherapy for MOGCTs are mostly irreversible and the severity is related to the chemotherapy cumulative dose. Identification of patients more likely to experience cisplatin-related toxicities could be based on several single-nucleotide polymorphisms [110]. MOGCTs: malignant ovarian germ cell tumors; CDCT: conventional-dose chemotherapy; TIP: paclitaxel/ifosfamide/cisplatin; HDCT: high-dose chemotherapy; ASCT: autologous stem cell transplant; TI-CE: paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide; OS: overall survival; PT: paclitaxel/cisplatin; BEP: bleomycin/etoposide/cisplatin; PFS: progression-free survival; IGCCC: international germ cell cancer consensus classification; GCT: germ cell tumors; FIGO: International Federation of Gynecology and Obstetrics; YST: yolk sac tumor; EC: embryonal carcinoma; AJCC: American Joint Committee on Cancer; COG: Children's Oncology Group; SCSTs: sex cord-stromal cell tumors; QoL: quality of life; CTH: chemotherapy.…”

Section: Management Of Malignant Ovarian Germ Cell Tumors (Mogcts)mentioning

confidence: 99%

Wise Management of Ovarian Cancer: On the Cutting Edge

Boussios

Mikropoulos

Samartzis

et al. 2020

JPM

Self Cite

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women. Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year survival rate is 20–40%. This heterogeneous group of malignancies has distinguishable etiology and molecular biology. Initially, single-gene sequencing was performed to identify germline DNA variations associated with EOC. However, hereditary EOC syndrome can be explained by germline pathogenic variants (gPVs) in several genes. In this regard, next-generation sequencing (NGS) changed clinical diagnostic testing, allowing assessment of multiple genes simultaneously in a faster and cheaper manner than sequential single gene analysis. As we move into the era of personalized medicine, there is evidence that poly (ADP-ribose) polymerase (PARP) inhibitors exploit homologous recombination (HR) deficiency, especially in breast cancer gene 1 and 2 (BRCA1/2) mutation carriers. Furthermore, extensive preclinical data supported the development of aurora kinase (AURK) inhibitors in specific tumor types, including EOC. Their efficacy may be optimized in combination with chemotherapeutic or other molecular agents. The efficacy of metformin in ovarian cancer prevention is under investigation. Certain mutations, such as ARID1A mutations, and alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway, which are specific in ovarian clear cell carcinoma (OCCC) and endometrioid ovarian carcinoma (EnOC), may offer additional therapeutic targets in these clinical entities. Malignant ovarian germ cell tumors (MOGCTs) are rare and randomized trials are extremely challenging for the improvement of the existing management and development of novel strategies. This review attempts to offer an overview of the main aspects of ovarian cancer, catapulted from the molecular mechanisms to therapeutic considerations.

show abstract

“…In general, epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, and because 70% of cases are diagnosed at stage III or IV 57,58 . Unlike EOC, malignant germ cell tumors (MGCT) typically occur in girls or young women, and is more sensitive to chemotherapy 59 . Therefore, EOC is associated with a worse prognosis compared with MGCT.…”

Section: Discussionmentioning

confidence: 99%

“…57,58 Unlike EOC, malignant germ cell tumors (MGCT) typically occur in girls or young women, and is more sensitive to chemotherapy. 59 Therefore, EOC is associated with a worse prognosis compared with MGCT. However, prognosis analysis on the basis of pathologic types in this study revealed no significant difference between EOC and MGCT.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Jiang

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: This study aims to investigate the safety and efficacy of chemotherapy in ovarian cancer patients in pregnancy. Methods: In this study, eligible studies were searched on PubMed, Embase, and Cochrane Library databases up to December 31, 2020. Data were calculated and presented by frequency and percentage, mean AE standard deviation (SD), and median (range), respectively. Kaplan-Meier survival analysis was performed to estimate overall survival (OS) and progression-free survival (PFS). Results: Finally, 34 studies including 40 ovarian cancer cases receiving chemotherapy during pregnancy were included. All 40 patients received chemotherapy during pregnancy. During the follow-up, seven of 37 (18.9%) women had a relapse and four of them (4/7, 57.1%) died of recurrence. Survival analysis failed to reach median OS and PFS within the follow-up (range 3-72 months). Better OS and PFS after chemotherapy in pregnancy were obtained in women with early-stage ovarian cancer (I) compared with those with advanced stage (III-IV). Neither OS nor FS differed between women treated with multi-drugs and those with monotherapy. Forty-one newborns were delivered from 40 pregnant women. Thirty-four (34/41, 82.9%) were completely healthy at birth and the end of follow-up (range 0.18-160 months). However, one newborn died 5 days after birth due to multiple congenital malformations, and another one developed Tourette's syndrome, aphasia, Asperger's syndrome as well as speech delay. Conclusions: This meta-analysis first reveals the efficacy and safety of chemotherapy for ovarian cancer during pregnancy, especially for early-stage patients. Cisplatin or carboplatin is suggested to be used as monotherapy to reduce adverse effects.

show abstract

Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches

Cited by 28 publications

References 47 publications

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis

Wise Management of Ovarian Cancer: On the Cutting Edge

Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta‐analysis of case reports and series

Contact Info

Product

Resources

About